Table 2 Summarization of clinical profiles of patients with anti-AMPAR encephalitis
Demographics | Range | Mean | N missing (%) |
|---|---|---|---|
Sex | 2 M/7F | 0 | |
Age (years) | 50–76 | 59 | 0 |
mRS (initial) | 1–5 | 4 | 0 |
mRS (last follow-up) | 0–6 | 5 | 2 (22) |
Onset to diagnosis (weeks) | 3–57 | 18 | 1 (11) |
Clinical symptoms | N | positive | N missing (%) |
Acute onset | 3 | 33% | 0 |
Subacute onset | 3 | 33% | 0 |
Chronic onset | 3 | 33% | 0 |
Amnesia | 8 | 89% | 0 |
Psychosis | 8 | 89% | 0 |
Ataxia | 2 | 22% | 0 |
Fever | 2 | 22% | 0 |
Sleep disorders | 2 | 22% | 0 |
Dysautonomia | 2 | 22% | 0 |
Numbness | 2 | 22% | 0 |
Dysarthria | 2 | 22% | 0 |
Dysphagia | 2 | 22% | 0 |
Deafness | 1 | 11% | 0 |
Altered levels of consciousness | 1 | 11% | 0 |
Involuntary movement | 1 | 11% | 0 |
Seizures | 0 | 0% | 0 |
Laboratory and MRI findings | N | Positive | N misssing (%) |
Only Blood AMPAR Ab (+) | 3 | 33% | 0 |
Only CSF AMPAR Ab (+) | 0 | 0% | 0 |
Blood and CSF AMPAR Ab (+) | 6 | 67% | 0 |
Other Onco-neuronal Abs | 2 | 33% | 3 (33) |
Increased CSF protein | 5 | 63% | 1 (11) |
Increased CSF WBC | 1 | 13% | 1 (11) |
MRI abnormal | 6 | 75% | 1 (11) |
EEG abnormal | 3 | 60% | 4 (44) |
Tumor identified | 6 | 67% | 0 |